Status:
TERMINATED
Pain Catastrophizing and Prescription Opioid Craving
Lead Sponsor:
Stanford University
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Chronic Pain
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Adherence to prescription opioid and opioid tapering as indicated are critical for safe chronic opioid therapy for chronic pain, but this can be difficult for patients experiencing prescription opioid...
Detailed Description
Chronic pain and opioid overdose are two critical public health problems in the US. About 25 million adults (11%) suffer from chronic daily pain and up to 8 million use opioids to manage chronic pain....
Eligibility Criteria
Inclusion
- At least 18 years
- Chronic pain ( \> 3months)
- Prescription opioid use (\>3 months)
Exclusion
- Current diagnosis of cancer
- Concurrent psychological therapy
- Other severe psychiatric conditions (schizophrenia, delusional disorder, psychotic disorder, dissociative disorder, and active suicidality)
- Any skin conditions on the hand (pain testing site)
- Non-English speaker
- No access to email or smart phone
Key Trial Info
Start Date :
June 29 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
97 Patients enrolled
Trial Details
Trial ID
NCT04097743
Start Date
June 29 2021
End Date
December 31 2024
Last Update
March 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford Pain Relief Innovations Lab
Palo Alto, California, United States, 27604